Adaptive Biotechnologies (NASDAQ:ADPT) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Adaptive Biotechnologies (NASDAQ:ADPT) announced its earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03, FiscalAI reports. The company had revenue of $70.87 million during the quarter, compared to the consensus estimate of $61.03 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The firm’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.20) earnings per share.

Here are the key takeaways from Adaptive Biotechnologies’ conference call:

• MRD momentum and guidance — MRD revenue grew 53% year?over?year to $67.1M in Q1 and management raised full?year MRD revenue guidance to $260M–$270M (includes a $9M milestone recognized in Q1).
• Margin and profitability progress — sequencing gross margin expanded to 70% (up 8 pts YoY) and MRD delivered positive adjusted EBITDA of $12.1M, with the company targeting >70% sequencing gross margins and positive adjusted EBITDA and free cash flow by end of 2026.
• Biopharma validation and backlog — bookings drove a pharma backlog of about $254M (up 24% YoY), including registrational studies and the company’s first recognized primary?endpoint milestone (CEPHEUS), signaling stronger, higher?value pharma demand for MRD endpoints.
• Clinical adoption and reimbursement traction — clonoSEQ set a quarterly volume record (~632,600 tests), blood?based testing rose to 49% of MRD volume, community testing grew 67% YoY to 35% of volumes, U.S. ASPs increased 11% to $1,360, and clonoSEQ was listed in the Texas Medicaid Policy Manual.
• Immune Medicine remains a drag — Immune Medicine revenue fell 26% to $3.8M with an adjusted EBITDA loss of $10.4M, and management expects IM cash burn of $15M–$20M for 2026 while commercialization/partnerships are still being developed.

Adaptive Biotechnologies Stock Performance

NASDAQ ADPT traded down $0.72 during trading hours on Tuesday, reaching $13.78. 3,176,459 shares of the company were exchanged, compared to its average volume of 1,541,203. Adaptive Biotechnologies has a 1 year low of $8.38 and a 1 year high of $20.76. The business’s 50 day simple moving average is $14.32 and its 200-day simple moving average is $15.92.

Insider Transactions at Adaptive Biotechnologies

In related news, COO Julie Rubinstein sold 19,037 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $14.23, for a total transaction of $270,896.51. Following the completion of the sale, the chief operating officer owned 377,802 shares in the company, valued at approximately $5,376,122.46. This trade represents a 4.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chad M. Robins sold 37,263 shares of the firm’s stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $15.19, for a total transaction of $566,024.97. Following the sale, the chief executive officer owned 2,180,518 shares of the company’s stock, valued at $33,122,068.42. This trade represents a 1.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 2,419,313 shares of company stock valued at $34,192,596 in the last 90 days. 5.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Adaptive Biotechnologies

Large investors have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. purchased a new position in shares of Adaptive Biotechnologies in the fourth quarter worth about $51,000. Strive Financial Group LLC purchased a new position in shares of Adaptive Biotechnologies in the fourth quarter worth about $52,000. Persistent Asset Partners Ltd purchased a new position in shares of Adaptive Biotechnologies in the fourth quarter worth about $109,000. Vinva Investment Management Ltd purchased a new position in shares of Adaptive Biotechnologies in the fourth quarter worth about $135,000. Finally, Quadrant Capital Group LLC purchased a new position in shares of Adaptive Biotechnologies in the third quarter worth about $133,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. BTIG Research upped their price objective on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Guggenheim upped their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Monday, April 20th. Piper Sandler set a $21.00 price objective on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $19.43.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.